Last $1.92 USD
Change Today +0.02 / 1.05%
Volume 362.3K
CDXS On Other Exchanges
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

codexis inc (CDXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/14 - $2.65
52 Week Low
12/24/13 - $1.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CODEXIS INC (CDXS)

codexis inc (CDXS) Related Businessweek News

View More BusinessWeek News

codexis inc (CDXS) Details

Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

125 Employees
Last Reported Date: 03/13/14
Founded in 2002

codexis inc (CDXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $592.0K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $334.8K
Special Advisor
Total Annual Compensation: $68.8K
Compensation as of Fiscal Year 2013.

codexis inc (CDXS) Key Developments

Codexis, Inc. - Special Call

To discuss the strategic collaboration and license agreement with GSK

Codexis Signs Platform Technology License Agreement with GlaxoSmithKline

Codexis, Inc. announced that it has signed a platform technology license agreement with GlaxoSmithKline plc. Under the terms of the agreement, Codexis granted GlaxoSmithKline a license to use its proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The license allows GlaxoSmithKline to use Codexis' platform technology to develop novel enzymes for use in the manufacture of its pharmaceutical and health care products. GlaxoSmithKline may also use the licensed technology to develop new therapeutic, diagnostic and prophylactic products in the human health field. Upon completion of technology transfer, GlaxoSmithKline will have Codexis' CodeEvolver protein engineering platform installed at its Upper Merion, Pennsylvania research and development site. Codexis is eligible to receive up to $25 million over approximately the next two years, $6 million of which will be paid upfront shortly after signing and an additional $19 million subject to satisfactory completion of technology transfer milestones. Codexis also has the potential to receive numerous additional milestone payments that range from $5.75 million to $38.5 million per project based on GlaxoSmithKline's successful application of the licensed technology. In addition, Codexis will be eligible to receive royalties based on net sales, if any, of a limited set of products developed by GSK using Codexis' CodeEvolver protein engineering platform technology.

Codexis, Inc. Announces Management Changes

On June 25, 2014, David O'Toole resigned from his position as the Senior Vice President and Chief Financial Officer and principal financial and accounting officer of Codexis, Inc. Mr. O'Toole's resignation will be effective July 3, 2014. The company has engaged an executive search firm to assist the company in recruiting a new Chief Financial Officer. On June 27, 2014, the Board of Directors of the Company appointed David McCaman, currently the Company's Vice President and Corporate Controller, as principal financial officer and principal accounting officer on an interim basis, effective upon the effectiveness of Mr. O'Toole's resignation. Mr. McCaman, age 56, has served as the Company's Vice President and Corporate Controller since May 2013. Prior to joining the Company, Mr. McCaman was the Chief Accounting Officer for Good Technology from July 2012 to April 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXS:US $1.92 USD +0.02

CDXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cambrex Corp $21.60 USD +0.96
Koninklijke DSM NV €52.57 EUR +0.47
Novozymes A/S kr282.60 DKK +1.00
Takasago International Corp ¥485.00 JPY +2.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CDXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CODEXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at